ecteinascidin 743 has been researched along with Rhabdomyolysis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hayakawa, K; Iwata, S; Kobayashi, H; Oka, H; Tanaka, S; Ueda, T; Wakamatsu, T; Wasa, J; Yonemoto, T | 1 |
| Albano, A; Guida, M; Lorusso, V; Strippoli, S | 1 |
| Judson, I; Martin-Liberal, J | 1 |
| Blay, JY; Delaloge, S; Demetri, GD; Frontelo, P; Jiao, JJ; Le Cesne, A; Maki, RG; Misset, JL; Nieto, A; Yovine, A | 1 |
| Alfaro, V; Cartoafa, M; D'Incalci, M; Fernández-Teruel, C; Gómez, J; Grosso, F; Judson, I; Kahatt, C; Lardelli, P; Nieto, A; Roy, E; Soto-Matos, A | 1 |
| Beldner, M; Kraft, A; Montero, AJ; Skorupa, A | 1 |
1 review(s) available for ecteinascidin 743 and Rhabdomyolysis
| Article | Year |
|---|---|
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dioxoles; Humans; Rhabdomyolysis; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
1 trial(s) available for ecteinascidin 743 and Rhabdomyolysis
| Article | Year |
|---|---|
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents, Alkylating; Child; Dioxoles; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Rhabdomyolysis; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
4 other study(ies) available for ecteinascidin 743 and Rhabdomyolysis
| Article | Year |
|---|---|
Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Body Height; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Neutropenia; Product Surveillance, Postmarketing; Progression-Free Survival; Retrospective Studies; Rhabdomyolysis; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Young Adult | 2020 |
Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin.
Topics: Dioxoles; Herb-Drug Interactions; Humans; Liposarcoma; Male; Middle Aged; Photinia; Plant Extracts; Rhabdomyolysis; Tetrahydroisoquinolines; Trabectedin | 2013 |
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Marrow; Creatine Kinase; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dioxoles; Female; Humans; Male; Middle Aged; Multivariate Analysis; Rhabdomyolysis; Tetrahydroisoquinolines; Trabectedin | 2012 |
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Fatal Outcome; Humans; Male; Middle Aged; Rhabdomyolysis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2007 |